Search

Agalsidase alfa

Agalsidase alfa is a recombinant human α-galactosidase A similar to [agalsidase beta]. … [A220343] Agalsidase alfa was granted EMA approval on 3 August 2001.[L16413]

Pegunigalsidase alfa

[A259352,L46342] Unlike other forms of recombinant alpha-galactosidase A, such as [agalsidase alfa] and [agalsidase beta], pegunigalsidase alfa uses a plant cell-based protein expression system, leading … While agalsidase alfa and agalsidase beta enter lysosomes via the mannose-6-phosphate (M6P) receptor, pegunigalsidase alfa carries no M6P on its glycans and does not depend on the M6P receptor during cellular

Cipaglucosidase alfa

Compared to alglucosidase alfa, cipaglucosidase alfa has a higher M6P content. … [A232955] Other types of enzyme replacement therapy for the treatment of Pompe disease include [alglucosidase alfa] and [avalglucosidase alfa].

Peginterferon alfa-2a

Peginterferon alfa-2a is derived from the alfa-2a moeity of recombinant human interferon and acts by binding to human type 1 interferon receptors. … The use of Peginterferon alfa-2a has largely declined since newer interferon-free antiviral therapies have been developed.

Edetate copper disodium

Efgartigimod alfa

[A243759,A243784] Efgartigimod alfa is a first-in-class[L39501] antagonist of the neonatal Fc receptor (FcRn) used in the treatment of MG. … Efgartigimod alfa for intravenous use was granted FDA approval on December 17, 2021[L39501] and European Commission approval on August 11, 2022 for use in patients with myasthenia gravis.

Avalglucosidase alfa

First developed by Sanofi Genzyme, avalglucosidase alfa is a chemically modified version of [alglucosidase alfa], where synthetic bis-phosphorylated oligosaccharides were attached to the structure to improve … [A232955] Avalglucosidase alfa is a recombinant form of GAA that restores deficient enzyme levels.

Velmanase alfa

[A244509] In February 2023, the FDA also approved velmanase alfa for the same indication.[L45295] Velmanase alfa is currently not approved in Canada. … Velmanase alfa is a recombinant human lysosomal alpha-mannosidase developed for enzyme replacement therapy to treat alpha-mannosidosis.

Andexanet alfa

It also prevents andexanet alfa from taking up space on phospholipid surface membranes, so that native FXa may bind and assemble the prothrominase complex [A35558]. … The procoagulation potential of andexanet alfa is eliminated through the removal of a 34-residue fragment containing Gla: via this truncation, andexanet alfa is unable to bind to membrane surfaces and

Doxepin

Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to cidoxepin. Doxepin commonly produces a 5:...